Clinical trials: Yellow Fever
Yellow Fever
Complementary Study of the Duration of Post-vaccination Against Yellow Fever Immunity in Children
In a previous study by the researchers' group, the researchers' investigate the duration of yellow fever post-vaccination immunity in vaccinated children between 9 and 23 months of age.
- Trial name
- NCT02990182
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Oswaldo Cruz Foundation
Yellow Fever
A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL
The study is designed as a Phase III, double-blind, multicenter, randomized, active-controlled, parallel-group design in which two groups of participants will receive either SII-YFV or STAMARIL® - a licensed and WHO pre-qualified…
- Trial name
- NCT05421611
- Testing
- STAMARIL, SII-YFV
- Where
- 2 sites in Kenya
- Volunteers
- 1,824 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Yellow Fever
Immunity After Two Doses of Yellow Fever Vaccine
To evaluate the immune status of yellow fever in adults with a history of two or more doses of vaccine, having received the second dose for at least 1 year, compared to re-vaccinated individuals (second dose) after 30 days.
- Trial name
- IATDYFV (NCT02572518)
- Where
- Brazil
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Yellow Fever
Passive Enhanced Safety Surveillance of Stamaril® Vaccine in Korea
This is a passive enhance safety surveillance (ESS) of Stamaril® vaccine in Korea. The objective is to collect suspected related adverse events following vaccination with Stamaril® in routine practice.
- Trial name
- NCT03541694
- Testing
- Stamaril®
- Where
- South Korea
- Volunteers
- 622 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company